Orphazyme ApS develops new therapies for the treatment of rare and genetic diseases. Its core program is to develop heat shock protein based therapies for the treatment of diseases caused by defects in the function and/or metabolism of proteins.
To read more about this, visit our here.Accept
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.